Opinion|Videos|July 12, 2024
Where Does Axatilimab Fit in the Treatment Lineup?
Experts on graft-vs-host disease discuss the potential role for axatilimab within current treatment algorithms.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What were the key findings from the AGAVE-201 trial presented at the 2023 ASH meeting?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- Were there any notable differences in efficacy or safety profiles observed across the different treatment arms?
- How did the different dosing regimens of axatilimab compare in terms of objective response rates, duration of response, and steroid dose reduction?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5